Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 11/20 | 0.52 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.52 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.52 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442280 | 0.96 | ACVR1 (0.47) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17442436 | 0.95 | ACVR1 (0.58) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL26867327 | 0.87 | ACVR1 (0.60) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17448612 | 0.85 | ACVR1 (0.43) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409706 | 0.83 | ACVR1 (0.53) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17441658 | 0.82 | ACVR1 (0.59) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17442313 | 0.81 | ACVR1 (0.68) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409635 | 0.81 | ACVR1 (0.70) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL23988812 | 0.81 | KDR (0.58) | ACVR1BMPR1ABMPR1BACVRL1KDR | |
| SCHEMBL19110527 | 0.81 | KDR (0.54) | ACVR1BMPR1ABMPR1BACVRL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022098812-A1 | METHODS OF TREATING IRON OVERLOAD | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098821-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099166-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | ACVR1 3/4885BMPR1A 32/4885BMPR1B 33/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | ACVR1 12/4885BMPR1A 7/4885BMPR1B 8/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | ACVR1 13/4885BMPR1A 8/4885BMPR1B 5/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | ACVR1 16/4885BMPR1A 10/4885BMPR1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.